BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study

Management of neurogenic detrusor overactivity (NDO) remains a clinical priority to improve patients’ quality of life and prevent dramatic urological complications. Intradetrusor injection of onabotulinumtoxinA (BoNT/A1, botulinum neurotoxin A1) is approved as second therapeutic line in these patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Maignel, Jacquie, Martin, Vincent, Assaly, Rana, Vogt, Mathieu L., Retailleau, Kevin, Hornby, Fraser, Laugerotte, Alexandra, Lezmi, Stéphane, Denys, Pierre, Krupp, Johannes, Joussain, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877829/
https://www.ncbi.nlm.nih.gov/pubmed/35202105
http://dx.doi.org/10.3390/toxins14020077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877829/
https://www.ncbi.nlm.nih.gov/pubmed/35202105
http://dx.doi.org/10.3390/toxins14020077

Ejemplares similares